BACKGROUND: The benefits of inhaled @entity288 in @entity565 are well established. Early use of inhaled anti-inflammatories following and exacerbation could be beneficial. METHODS: A retrospective observational cohort study compared the risk of @entity565 -related exacerbations [hospitalization, emergency department visit, and/or treatment with systemic corticosteroid] in @entity1 receiving treatment with @entity5023 / @entity10453 in a single inhaler ( @entity24839 ) within 90 days following an initial @entity565 -related exacerbation (early treatment) versus @entity1 receiving the treatment subsequently (late treatment). Data were from a large health insurance claims database spanning from January 1998 to April 2008. Subjects included @entity1 with >= 1 prescription for @entity24839 year after first @entity565 -related exacerbation. @entity1 with early treatment were matched to those with late treatment by propensity score and compared in terms of healthcare utilization and costs after initiation of @entity24839 . RESULTS: A total of 14,861 @entity1 met study inclusion criteria, including 10,793 early and 4068 late treatment @entity1 . After matching, 3555 pairs were well matched on all pretreatment characteristics and duration of follow-up (mean 722 vs. 717 days, p = .634). Early versus late treatment was associated with longer time to first @entity565 -related exacerbation (hazard ratio = 0.82, 95% CI 0.75-0.88, p < .001), fewer short-acting b-agonists prescriptions (3.3 vs. 3.6, p = .031), higher outpatient yearly per @entity1 pharmacy costs ( 1320 vs.  1163, p = .008), and lower yearly per @entity1 @entity565 -related emergency department visit costs ( 80 vs.  105, p = .032). Total yearly per @entity1 @entity565 -related costs were similar ( 2197 vs.  2064, p = .203). CONCLUSIONS: Earlier use of @entity24839 following an @entity565 exacerbation was associated with reduced risk of future @entity565 -related exacerbation and lower use of rescue medications.

Retrospective comparison of early versus late treatment with @entity5023 / XXXX after an @entity565 exacerbation.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity24839 :: ('8852', 'Gene') :: ['FSC  <= 1', 'FSC'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity10453 :: ('MESH:C057823', 'Chemical') :: ['salmeterol'] @entity5023 :: ('MESH:C065382', 'Chemical') :: ['fluticasone propionate'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity10453 :: (MESH:C057823,Chemical) :: ['salmeterol']
